Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL

(6:13)

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

(48)

Dr. Sharman - Immunotherapy

(2:1econd)

Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma

(2:51)

Sharman MD-3500 \u0026 MD-7400 HF Slider Antenna

(2:20)

Dr. Sharman on Remaining Challenges With BTK Inhibitors in CLL

(1:6)

Maheroo Maheroo - Lyrical | Super Nani | Sharman Joshi, Shweta K | Shreya Ghoshal | Sanjeev Darshan

(4:49)

Mufti Ishaq Mohammad Abul Khair || Chormonai New Waz || Bangla Waz 2023 || @muslimrecordingcenter

(21:18)

What is Shamanism? Explained by shamanic expert Roger Walsh, MD, PhD.

(4:57)

Bangla waz charmonai । Koborer Ajab কবরের আজাব । Maulana Fazlul karim Rah. One Music Islamic

(58:36)

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019

(1:52)

A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24

(7:31)

Dr. Sharman on the Potential Approval of Acalabrutinib in CLL

(1:47)

Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies

(2:14)

Jeff Sharman, MD, shares results of the GENUINE phase 2 study presented at ASCO 2017

(1:34)

Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax

(1:42)

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

(2:37)

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

(1:39)

Exploring Novel Mechanisms in Chronic Lymphocytic Leukemia

(3:10)

Coos Bay - North Bend Rotary: Covid-19 Update from Dr. Kent Sharman, North Bend Medical Center

(40:29)

Jeff Sharman, MD, comments on emerging trends in CLL management

(1:23)

Dr. Jeff Sharman: A discussion about combination therapy

(3:20)

Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019

(1:47)

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients

(3:53)